Scilex Holding Company Deposits, Fair Value Disclosure
Scilex Holding Company (SCLX) had Deposits, Fair Value Disclosure of $14.69 million as of 2024-09-30, per its 10-Q filed 2025-01-17.
Financial Statements › Notes › Fair Value Disclosures › Financial Instruments, Financial Liabilities, Balance Sheet Groupings
us-gaap:DepositsFairValueDisclosure · last filed 2025-01-17
- 2024-09-30: Deposits, Fair Value Disclosure $14.69M.
- 2024-06-30: Deposits, Fair Value Disclosure $11.73M.
| Period end | Deposits, Fair Value Disclosure |
|---|---|
| 2024-09-30 | $14.69M 10-Q · filed 2025-01-17 |
| 2024-06-30 | $11.73M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |